$1M gift furthers UNC research on breast cancer disparities, barriers to high-quality care

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Rich Preyer and Marilyn Jacobs Preyer of Hillsborough, North Carolina donated $1 million to support the latest phase of UNC Lineberger Comprehensive Cancer Center’s Carolina Breast Cancer Study, which is investigating how the causes, treatments, and long-term outcomes of breast cancer differ between Black and white women. 

Researchers from UNC Lineberger and UNC Gillings School of Global Public Health launched the Carolina Breast Cancer Study in 1993 to identify a wider range of breast cancer risk factors and to better understand how these risk factors contribute to disparities in breast cancer. 

The study focuses on the biological and social determinants of health—from pathology, molecular markers, and genetics on the cellular level, to health care access, the financial burden of care, and quality of life following diagnosis. 

The next phase of the study, phase IV, will utilize high-end computing to analyze image data from histopathology and mammograms, enabling scientists to develop a more robust model of disparities and breast cancer outcomes. The researchers will also focus on doubling the number of young women and Black women participating in the research.

The private funds will help researchers expand the study to include more participants and lay the foundation for pursuing additional funding sources going forward.

This gift counts toward the Campaign For Carolina, UNC’s most ambitious fundraising campaign in history, launched in October 2017 with the goal of raising $4.25 billion by December 2022.

The Carolina Breast Cancer Study is funded in part by the University Cancer Research Fund, the NCI’s SPORE in breast cancer, and Susan G. Komen.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login